<unk>  <unk>  belongs to one the rare hereditary platelet disorders.<unk>  characteristically is defined by the presence of giant platelets and thrombocytopenia.<unk>  <unk>  was first discovered in 1948.<unk>  may be classified into 4 subtypes.<unk>  is the result of the absence or decreased expression of the GPIb/IX/V complex on the surface of the platelets.<unk>  may be caused by abnormality in the genes for glycoprotein Ib/IX/V. The prevalence of<unk>  is approximately 1 per 100,000 individuals worldwide. The initial laboratory test to be done is blood cell counts and blood smears. There are no established risk factors for<unk> . There is sufficient evidence to recommend routine screening for<unk>  with newer technologies in current clinical practice. If left untreated, patients with<unk>  may progress to develop bleeding manifestations like mucocutaneous bleeding, which can be prolonged and severe. Patients with<unk>  usually remarkable for dysfunctional platelets. There is no specific treatment for<unk> , the mainstay of therapy is supportive care.
Bernard-Soulier syndrome
Ehlers-Danlos syndrome
Ehlers–Danlos syndrome
Klein-Levin syndrome
Von Willebrand disease
Yunis-Varon syndrome
Grey platelet syndrome
Patau syndrome